Heptares Therapeutics
Emma Tripp started their work experience in 2016 as a Waitress at The Buntingford Kitchen. In 2016-2017, they worked as a Masters Student at the Cell Biophysics Laboratory, where they focused on assessing kinase interactions and activation states in breast cancer cell models. From 2018 to 2022, Emma worked as a PhD student at the University of Birmingham, specializing in their research. In 2018, they also served as a Web Team Assistant at MS Trust for a short period. In 2019, Emma interned as a Science Coordinator at The Royal Institution. Currently, they are a Research Scientist at Sosei Heptares, starting in 2022.
Emma Tripp completed their education with a Doctor of Philosophy (PhD) degree in Metabolic diseases from the University of Birmingham, where they studied from 2018 to 2022. Prior to that, they obtained a Master's Degree in Pharmacology from the University of Bath from 2014 to 2018. Emma's earlier education includes attending The Hertfordshire and Essex High School and Science College from 2007 to 2014, although the specific degree and field of study are not mentioned. In addition to their formal education, Emma also obtained a certification in "An Introduction into Quantitative Biology" from SysMIC.ac.uk in September 2020.
This person is not in the org chart
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.